Author Archive for: TG

AstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub.

Paris-based One Biosciences, a pioneering “techbio” company at the intersection of artificial intelligence and oncology, has announced a €15 million Series A funding round to accelerate the clinical application of its flagship technology.

That deserves a closer look: The recently announced partnership between Axxam S.p.A., a leading provider of integrated early discovery services, and Molecular Health GmbH, a pioneer in AI-powered data solutions for pharmaceutical R&D, is more than a standard collaboration. It exemplifies the convergence of consolidated in-vitro biology-led drug discovery with modern, data-intelligent drug development methodologies. As an example for breaking the silos of clinical and preclinical target validation.

The planned US$10 billion acquisition of UK-based Verona Pharma by US pharmaceutical giant Merck & Co. underscores several key dynamics reshaping the global biotech industry. Not only does the deal reflect Merck’s strategic push to diversify in anticipation of the looming patent expiry of its blockbuster cancer drug Keytruda, but it also highlights the growing appeal of European biotech for US investors.

The British Food Standards Agency (FSA) has formally accepted an application by French start-up Gourmey SAS for regulatory approval of its cultivated foie gras, a product developed using cellular agriculture techniques. The submission was initially lodged on 26 July 2024 and was made in parallel across five jurisdictions: the European Union, United States, Singapore, Switzerland, and the United Kingdom.